¹**Proof-of-concept: SCENTinel 1.1 rapidly** ²**discriminates COVID-19 related olfactory** ³**disorders**

- 4
- 5 Stephanie R. Hunter^{1†}, Mackenzie E. Hannum^{1†}, Robert
- 6 Pellegrino¹, Maureen A. O'Leary¹, Nancy E. Rawson¹, Danielle
- 7 R. Reed¹, Pamela H. Dalton¹, Valentina Parma^{1,2*}
-

9 ¹ Monell Chemical Senses Center, Philadelphia, PA

- ² Department of Psychology, Temple University, Philadelphia, PA
- 11 $^{\dagger}$ Equal contributions
- 12
- 13
- 14 ***Correspondence:**
- 15
- 16 Valentina Parma, PhD
- 17 Monell Chemical Senses Center
- 18 3500 Market Street
- 19 Philadelphia, PA 19143
- 20 Email: vparma@monell.org
- 21
- 22 **Keywords:** Anosmia, hyposmia, parosmia, phantosmia, prediction, smell test 23

24 **Abstract**

25 It is estimated that 20-67% of those with COVID-19 develop olfactory disorders, depending on 26 the SARS-CoV-2 variant. However, there is an absence of quick, population-wide olfactory tests 27 to screen for olfactory disorders. The purpose of this study was to provide a proof-of-concept 28 that SCENTinel 1.1, a rapid, inexpensive, population-wide olfactory test, can discriminate 29 between anosmia (total smell loss), hyposmia (reduced sense of smell), parosmia (distorted odor 30 perception), and phantosmia (odor sensation without a source). Participants were mailed a 31 SCENTinel 1.1 test, which measures odor detection, intensity, identification, and pleasantness, 32 using one of four possible odors. Those who completed the test $(N = 381)$ were divided into 33 groups based on their self-reported olfactory function: quantitative olfactory disorder (anosmia 34 or hyposmia, $N = 135$), qualitative olfactory disorder (parosmia and/or phantosmia; $N = 86$), and 35 normosmia (normal sense of smell; $N = 66$). SCENTinel 1.1 accurately discriminates 36 quantitative olfactory disorders, qualitative olfactory disorders, and normosmia groups. When 37 olfactory disorders were assessed individually, SCENTinel 1.1 discriminates between hyposmia, 38 parosmia and anosmia. Participants with parosmia rated common odors less pleasant than those 39 without parosmia. We provide proof-of-concept that SCENTinel 1.1, a rapid smell test, can 40 discriminate quantitative and qualitative olfactory disorders, and is the only direct test to rapidly 41 discriminate parosmia.

42

44 Introduction

67 [7]. Currently validated smell tests, such as UPSIT [16,19–24], Sniffin' Sticks [25–27], or the 68 NIH Toolbox Odor Identification Test [28], among others, are sensitive at accurately identifying 69 quantitative olfactory disorders, including anosmia and hyposmia. However, these tests lack 70 suitability for population-wide surveillance of smell function, especially during the COVID-19 71 pandemic, due to their odor delivery method, increased cost and time to execute, and/or because 72 the test cannot be self-administered.

73 To address these shortcomings in olfactory testing, we created the SCENTinel Rapid 74 Smell Test [29]. The first version of the test, SCENTinel 1.0, is a self-administered test that uses 75 flower as a target odor to assess odor detection ("select the patch with the strongest odor ''), odor 76 intensity ("rate the intensity of the odor" using a visual analog scale from 1–100), and odor 77 identification ("identify the odor" when given four picture/label options). To enable the use of 78 SCENTinel as a rapid test of smell function, accuracy criteria were established: odor detection 79 and odor identification answers are coded as correct or incorrect and odor intensity uses a cutoff 80 of 20 to determine normal smell function (i.e., normosmia), based on a previous study by Gerkin 81 et al [5]. These three subtests are then combined to create an overall score, which was previously 82 found to differentiate between people self-reporting anosmia from normosmia [29].

83 Many of the direct approaches to assess olfactory function only focus on quantitative 84 smell disorders and there remains a dearth of direct tests that discriminate for qualitative 85 olfactory disorders, including parosmia and phantosmia. Often, qualitative olfactory disorders 86 are diagnosed through subjective ratings from questionnaires and/or patient history obtained 87 through interviews [30–35]. This reliance on self-report leaves estimates of qualitative olfactory 88 disorders likely underrepresented, only diagnosed when individuals consult specialists. However, 89 even with subjective reports, qualitative olfactory disorders are present in more than half of those

90 reporting smell impairment [36–38], and distinct features of parosmia and phantosmia are 91 beginning to surface [31]. Parosmia encompasses distortions of a known odor, often 92 experiencing pleasant odors as unpleasant or vice versa [39], so one way to assess parosmia 93 directly is to have participants rate the pleasantness of two oppositely valenced odors (i.e., a 94 pleasant and unpleasant odor). This procedure creates a hedonic score, such that those with 95 parosmia have a lower hedonic score than those with normosmia, assuming those with parosmia 96 would rate the pleasant odor as unpleasant. Liu and colleagues successfully employed this 97 technique to classify two patients with parosmia [27]. Directly testing for parosmia may still 98 prove difficult, because parosmia reports are not consistent across all odors. Odors that are 99 frequently associated with parosmia include coffee, meats, onion, garlic, and chocolate [2,31,40], 100 yet the direct cause for the odor-specificity remains to be understood. Individuals with odor-101 specific parosmia may only be detected with direct smell tests if the distorted odor is used in the 102 test, and therefore, multiple odor versions are needed. Overall, there is a pressing need to directly 103 measure quantitative and qualitative olfactory disorders in a fast and inexpensive way to enable a 104 better assessment of the magnitude of smell impairments in the population. Once validated 105 against gold-standards and normed, such tests may help to diagnose diseases where smell loss is 106 a symptom (including head trauma [41–43], neurodegenerative diseases [44–46], and viral 107 illness [47]), and help evaluate the impact of treatments and therapies for those living with 108 olfactory disorders.

109 Here, we extend SCENTinel 1.0 to a new version, SCENTinel 1.1, with the goal to 110 discriminate between quantitative and qualitative olfactory disorders. Using the rationale from 111 Liu et al. [27], we include a hedonic score subtest to discriminate qualitative olfactory disorders 112 population-wide. Specifically, after participants complete the odor detection, intensity, and

113 identification subtests, they will rate the pleasantness of two oppositely valenced odors (the 114 actual odor on the SCENTinel test received, and an imagined, universally unpleasant odor) to 115 create a hedonic score to directly measure parosmia and phantosmia. Using two odors enables a 116 common anchor between the hedonic scores to account for varying scale usage. Additionally, 117 SCENTinel 1.1 includes four target odor versions: flower (the same odor in SCENTinel 1.0), 118 bubblegum, coffee, and caramel popcorn (Supplementary Table S1), enabling SCENTinel to be 119 used for repeat testing (12 different odor/placement combinations) and to capture potential odor-120 specific olfactory symptoms. 121 In the present study, we sought to test the ability of SCENTinel 1.1 to discriminate 122 different smell disorders through three aims. First, we aim to validate the ability of SCENTinel 123 1.1 (with multiple target odors) to discriminate between those with normosmia and anosmia, 124 based on the original model developed with SCENTinel 1.0 (with one target odor) [29]. We 125 hypothesize that SCENTinel 1.1 will discriminate between participants with normosmia and 126 anosmia similarly to that reported in SCENTinel 1.0. 127 Second, we aim to determine SCENTinel 1.1's accuracy in distinguishing between 128 quantitative (anosmia and hyposmia) and qualitative (parosmia and phantosmia) olfactory 129 disorders. Specifically, we expect those with quantitative olfactory disorders will rate the odor 130 intensity as low or absent and may not be able to distinguish the odor stimulus, therefore unable 131 to meet the accuracy criteria for odor detection, intensity and, likely, identification if they are 132 anosmic or severely hyposmic. Those with qualitative olfactory disorders may correctly detect 133 the odor and rate the intensity >20, but its quality may be distorted, so we hypothesized that they 134 would perform better overall on SCENTinel 1.1 compared to those with quantitative disorders, 135 but their odor identification ability might be jeopardized.

136 Finally, we aim to explore whether assessing odor pleasantness can accurately

137 discriminate those with parosmia. Experiencing distorted odors is often reported as an unpleasant

138 experience [39], therefore we hypothesized that those with qualitative olfactory disorders (i.e.,

- 139 parosmia) would report a lower hedonic score for common odorants included in SCENTinel 1.1
- 140 than those without distortion (e.g., people with hyposmia or normosmia).

141 Materials & Methods

142 The materials, procedures, hypotheses, and pre-analysis plan were pre-registered and are 143 publicly available in the Open Science Framework Repository [48].

144 **SCENTinel 1.1**

145 The SCENTinel 1.1 test card contains three patches created with Lift'nSmell technology 146 (Scentisphere, Carmel, NY), of which only one patch contains a target odor and the other two are 147 blank. SCENTinel 1.1 includes four subtests: odor detection accuracy (correct/incorrect); odor 148 intensity (above/below a cutoff of 20, or continuous value depending on the analysis); odor 149 identification among 4 given options (correct/incorrect) or, if the first response is incorrect, 150 among the 3 remaining options (correct/incorrect); and a hedonic score (pleasantness rating of an 151 unpleasant imagined odor (vomit) – pleasantness rating of the target odor on the SCENTinel test; 152 procedure outlined in Supplementary Fig. S1). The target odor on SCENTinel 1.1 is one of four 153 possible odors, such that participants received a SCENTinel 1.1 test with either a flower, a 154 coffee, a bubblegum, or a caramel popcorn target odor. However, note that there is only one odor 155 on each SCENTinel test. Therefore, participants smelled only one of the four possible odors. All 156 odors were from Givaudan (Cincinnati, OH; see Supplementary Table S1 for catalog numbers)

157 and were designed to be iso-intense at an intensity of 80 on a scale of 0 to 100, confirmed via 158 pilot testing.

159 **Participants**

160 Participants were recruited through two exclusive Facebook groups ("Covid-19 Smell 161 and Taste Loss" and "AbScent Parosmia and Phantosmia Support" hosted by AbScent, a charity 162 serving individuals with smell and taste disorders based in the UK), which were open to those 163 suffering from olfactory disorders due to COVID-19 and their family and friends. Interested 164 participants were instructed to complete an online survey to determine eligibility. Those who 165 reside in the United States, between 18-75 years old, and have access to a smart device or 166 computer were eligible for this study.

167 Of the 1290 individuals who completed the eligibility survey, 733 were eligible and were 168 mailed a SCENTinel 1.1 test on a first-come, first-served basis, and 512 participants completed 169 the test (response rate: 70%; see Figure 4 for a schematic overview). Participants were excluded 170 if they reported smell loss unrelated to COVID-19 ($N = 19$), illogical self-reported olfactory 171 disorders (e.g., selected both anosmia and hyposmia or anosmia and parosmia; $N = 30$), self-172 reported full recovery at the time of the SCENTinel test $(N = 2)$, a negative COVID-19 test (i.e., 173 no confirmed COVID-19 diagnosis; $N = 57$), undiagnosed smell loss (i.e., reported having a 174 current olfactory disorder other than anosmia, hyposmia, parosmia, or phantosmia; $N = 11$), or 175 incomplete data ($N = 12$). Ultimately, 348 participants with a smell disorder from laboratory-176 confirmed COVID-19 and 33 participants with normosmia were included in the final analyses. 177 Participants were assigned to smell groups based on their response to the question outlined in 178 Figure 4: 135 participants had only anosmia or hyposmia (quantitative olfactory disorder, 179 referred to as **quantitative OD group**), 86 had only parosmia or phantosmia (qualitative

203 each patch on the SCENTinel 1.1 card, one at a time, from left to right, and 1) select which patch 204 smells the strongest (odor detection), 2) rate how intense the odor was on a 100-point visual 205 analog scale (odor intensity), and 3) identify the odor out of four possible options (odor 206 identification). If they identified the odor incorrectly the first time, they were given a second 207 chance (three alternative-forced choice paradigm). Binary responses (correct/incorrect) to these 208 subtests (odor detection, odor intensity, and odor identification; note: odor intensity subtest had a 209 cut off of 20 out of 100) were used to calculate participants' overall score specified in a previous 210 publication [29]. Potential response strategies are outlined in Table 1. Participants then rated the 211 pleasantness of the odor on the card and the pleasantness of the smell of vomit (by imagining the 212 smell) using a 100-point visual analog scale anchored with "Very Unpleasant" at 0 and "Very 213 Pleasant" at 100. These pleasantness ratings were used to calculate a hedonic score [from –100 to 214 100] by subtracting the rating of the pleasantness of the odor on the card and the rating of the 215 pleasantness of imagined vomit. The hedonic score was not included in the SCENTinel 1.1 216 overall score. Participants also rated the frequency at which they experienced distorted or 217 phantom odors in the past week using a 100-point visual analog scale from 0 - "Never" to 100 - 218 "All the time". These questions were similar to those used to measure parosmia in Liu et al [27]. 219

220 **[INSERT TABLE 1 HERE]**

221 **Data Analysis**

222 This cross-sectional design included the between-subject factor "smell function" group 223 (quantitative OD, qualitative OD, normosmia; Figure 4) and the following within-subject factors: 224 meeting the accuracy criteria within SCENTinel 1.1 subtests (odor detection, intensity, 225 identification), overall score, as well as the new subtest, hedonic score. The intensity subtest had

288 **SCENTinel 1.1 with the four target odor variations maintains accurate performance in** 289 **anosmia discrimination.**

290 To assess the validity of the original model [29], and the impact of the features included 291 in SCENTinel 1.1 (e.g., multiple odor versions), we prospectively verified the ability of the 292 SCENTinel 1.0 classification model to predict the performance of individuals with anosmia and 293 normosmia in a new sample of participants with COVID-19-related smell loss tested with 294 SCENTinel 1.1. In Parma et al. 2021, the SCENTinel 1.0 classification model accurately

343

344 **SCENTinel 1.1 discriminates between self-reported anosmia, hyposmia, parosmia and**

345 **normosmia.**

346 Both quantitative and qualitative OD groups are inherently heterogeneous, and individual 347 olfactory disorders within each group can result in different performance on the SCENTinel 1.1 348 subtests and overall score. For example, within the quantitative OD group, individuals can have a 349 reduced sense of smell (hyposmia) or total smell loss (anosmia). Those with hyposmia are still 350 likely to accurately detect and identify the odor in the SCENTinel 1.1 test, but report a lower 351 odor intensity, whereas those with anosmia would likely not be able to accurately detect or 352 identify an odor on SCENTinel 1.1 without guessing. Given these inherent differences, we 353 determined how performance on SCENTinel 1.1 differentiated the three most common olfactory 354 disorders in our sample: hyposmia ($N = 84$), anosmia ($N = 51$), and parosmia ($N = 66$). The 355 SCENTinel 1.1 overall score accurately predicts group classification - discriminating hyposmia 356 from parosmia (AUC = 0.89), anosmia from parosmia (AUC = 0.82), and hyposmia from 357 anosmia (AUC = 0.78). Accuracy rates for all SCENTinel 1.1 subtests for participants with 358 anosmia, hyposmia, and parosmia can be found in Supplementary Table S2.

359

360 **Self-reported parosmia as captured by SCENTinel 1.1.**

361 We only assessed differences in the hedonic score between those with hyposmia, normosmia,

362 and parosmia. Participants with anosmia were not included in this analysis since rating the

363 pleasantness of an odor by those who cannot perceive it is meaningless. Furthermore, our results

364 confirm that excluding participants with anosmia from this analysis did not significantly 365 contribute to hedonic score differentiation (Supplementary Table S3). As expected, the hedonic 366 score was lowest for those with parosmia compared to those with hyposmia ($t = 3.42$, $p < 0.001$) 367 and normosmia (t = 2.06, p = 0.04; Figure 3A). There was no difference in hedonic score 368 between those with hyposmia and normosmia (t = 0.48, p = 0.64). Among those who had 369 parosmia, the majority of participants experienced odor distortions most of the time (Figure 3B). 370 Indeed, hedonic score and parosmia frequency were negatively correlated ($R = -0.21$, $p <$ 371 0.001), such that individuals who experienced parosmia more frequently had a lower hedonic 372 score compared to those who experience parosmia less frequently (Figure 3B). Given that there 373 was no difference in the hedonic score between those with hyposmia and normosmia, and to 374 isolate the effects of parosmia, we combined those with hyposmia and normosmia into one group 375 to compare the hedonic score between those with parosmia $(N = 66)$ and those without parosmia 376 (N = 150). Coffee is the only odor in SCENTinel 1.1 that is frequently reported to be distorted 377 with parosmia [35,40]. Therefore, we assessed whether there was an effect of the odor used in 378 SCENTinel 1.1 on the hedonic score. There was a significant group effect such that participants 379 with parosmia had lower hedonic scores compared to those without parosmia ($F_{3,285} = 13.78$, p < 380 0.001), but this did not differ between the four odors used in SCENTinel 1.1 ($F_{3,285} = 0.05$, p = 381 0.99; Figure 3C). Differences in the hedonic score were primarily driven by a lower pleasantness 382 ratings of the odor in the SCENTinel 1.1 test in those with parosmia ($t = 4.43$, $p < 0.001$), as 383 opposed to the imagined pleasantness rating of vomit which did not differ between those with 384 and without parosmia ($t = -0.57$, $p = 0.57$; Figure 3D). 385

386 Discussion

409 SCENTinel 1.1 still accurately discriminated between normosmia, quantitative OD, and 410 qualitative OD groups with acceptable sensitivity $(AUC > 0.7)$.

411 To reduce the heterogeneity, when we assessed how well individual smell groups 412 performed on SCENTinel 1.1, we found that SCENTinel 1.1 can discriminate between those 413 with anosmia, hyposmia, and parosmia. Despite the smaller sample size, SCENTinel 1.1 was 414 more sensitive at discriminating between anosmia, hyposmia, and parosmia groups than the 415 broad quantitative and qualitative OD group classifications, likely because the individual smell 416 groups are less heterogeneous classifications. Phantosmia was not included because of the 417 limited sample size $(N = 9)$. More research is needed to understand how those with phantosmia 418 perform on SCENTinel. Different SCENTinel 1.1 subtests were able to discriminate between 419 different groups. There was no difference in odor detection, but odor intensity was able to 420 discriminate anosmia from hyposmia, and parosmia. Odor identification and the hedonic score 421 discriminated between hyposmia and parosmia. The present study highlights the complexity of 422 classifying individual olfactory disorders, both quantitative and qualitative alike, with a rapid, 423 self-administered smell test. While we only included individuals with a single olfactory disorder 424 in our analyses, individuals can have a quantitative and qualitative olfactory disorder 425 simultaneously (e.g., hyposmia *and* parosmia), and it is rare to have a single qualitative olfactory 426 disorder alone [3]. One area of future research is to explore these complexities to better classify 427 olfactory disorders using SCENTinel.

428 The SCENTinel 1.1 overall score consistently discriminated between groups at rates 429 significantly better than chance, with a similar or higher accuracy than any subtest. Many other 430 smell tests only use one olfactory function (e.g., summed performance from odor identification) 431 to classify olfactory disorders [19,28]. However, our results show that while incorrectly

432 identifying an odor indicates that someone has an olfactory disorder, more information is needed 433 to determine whether the nature of such disorder is quantitative (indicating olfactory loss) or 434 qualitative (indicating olfactory distortions). Assessing odor detection, intensity, identification, 435 and hedonic score within the SCENTinel 1.1 test provides information about participants' 436 olfactory abilities beyond the usually tested olfactory identification. Measuring different 437 olfactory functions reveals response patterns commonly associated with different etiologies of 438 olfactory disorders [54]. For example, in a group of individuals with hyposmia from various 439 etiologies who completed the Sniffin' Sticks extended test battery (completion time ~45 mins), 440 those with hyposmia from Parkinson's disease performed well on odor threshold tests, but had 441 reduced odor detection and identification ability, likely because of impaired central olfactory 442 information processing. Those with hyposmia from sinonasal disease performed well on odor 443 detection and identification, but had poor olfactory thresholds, likely because of anatomical 444 obstruction, or inflammation and edema [54]. To the best of our knowledge, SCENTinel 1.1 is 445 the only tool that can screen for multiple olfactory functions in less than 5 minutes, and that has 446 the potential to provide etiological insight.

447 Including the hedonic score in SCENTinel 1.1 was successful in discriminating parosmia. 448 As hypothesized, participants with parosmia reported a lower hedonic score compared to 449 participants without parosmia, driven by a lower hedonic rating of the target odor on the 450 SCENTinel card, as the hedonic rating of the imagined vomit odor was not different between 451 participants with and without parosmia. This finding supports reports of individuals with 452 parosmia often finding odors to be unpleasant [39]. However, less commonly, some patient 453 reports have shown a valence flip - in addition to pleasant odors smelling unpleasant, reporting 454 odors typically experienced as foul are now pleasant [31,55,56]. To test this valence flip theory,

455 an actual unpleasant target odor may need to be experienced to capture the less-common 456 negative-to-positive hedonic experience, as our use of an imagined unpleasant odor was not 457 adequate. Furthermore, specific distortions have been reported, coffee being prominently 458 reported in interviews with patients who have parosmia [2,40]. However, we did not find any 459 significant difference in hedonic scores between the flower, coffee, bubblegum, or caramel 460 popcorn odors used in SCENTinel 1.1. Notably, we did not assess individual parosmia triggers in 461 the participants with parosmia, therefore it is unknown if coffee was a specific odor distortion in 462 our current sample. Someone with parosmia may still be able to guess the identity of an odor if 463 they know what their distortion is triggered by (for example, if coffee typically smells like 464 gasoline, and they smell gasoline on the smell test, they might accurately identify the odor as 465 coffee because of the association). Therefore, a hedonic score that assesses pleasantness 466 circumvents this issue of accurately identifying odors that are known distortions. Overall, our 467 findings partially support the rationale to use the hedonic score proposed by Liu et al [27], 468 capturing positive odors smelling negative. 469 More research is needed to account for the impact of varying etiologies of olfactory 470 disorders. Presently, SCENTinel 1.1 accurately predicted group classification in participants who 471 experienced olfactory disorders because of COVID-19, which supports the use of SCENTinel 1.1

472 to understand COVID-19 olfactory symptoms. It also supports the use of SCENTinel 1.1 as a

473 tool to help detect and monitor sudden loss of smell, which is a symptom of COVID-19 [5,57],

474 as well as parosmia, an evolving symptom of COVID-19 [31,36,37]. Early diagnosis of olfactory

475 impairment is critical for establishing successful outcomes to treatment regimens like olfactory

476 training [58] which has recently shown effectiveness with patients with parosmia [59].

477

478 *Limitations*

479 Participants were grouped based on their self-reported olfactory disorders. It is possible 480 that participants did not accurately classify their olfactory disorder [7,60]. To limit inaccurate 481 data, we asked specific questions describing their smell loss (Figure 4) and excluded participants 482 whose self-reported olfactory disorder did not fit conventional categories (i.e. someone who 483 reported having both anosmia and hyposmia). An area of future research is to directly screen for 484 smell function with another validated smell test to better understand how they perform on 485 SCENTinel. Granted, there are no direct, validated tests that diagnose parosmia aside from 486 SCENTinel 1.1. Until then, in-depth interviews would be necessary. Another limitation of this 487 study is that COVID-19 test results were also self-reported. However, participants in this study 488 were recruited from a Facebook group specifically for those with smell loss from COVID-19, 489 and specific questions describing the cause of their smell loss *(In your opinion, what might have* 490 *been the cause of your smell loss? Selected "COVID-19"*), and their COVID-19 test results 491 [What was the test result? 1) Selected "Positive Lab Test (COVID+)"] were included to 492 eliminate participants who had smell loss unrelated to COVID-19 and reduce heterogeneity. 493 Nevertheless, SCENTinel 1.1 was designed to test for olfactory disorders regardless of the 494 etiology; thus, inaccurate reports of COVID-19 diagnosis are not expected to alter the results. 495 However, this is another area where future studies are needed. Finally, SCENTinel 1.1 uses one 496 of four different odors in each test. Including more odor options, particularly unpleasant odors, 497 may help to better measure and understand parosmia. Not all odors are equally distorted in those 498 who experience parosmia [40]. The four odors used in SCENTinel 1.1 may not have been odors 499 that were distorted in the participants with parosmia.

500

501 Conclusion

- 503 within olfactory disorders, often takes time and specialty expertise. Despite being a rapid,
- 504 inexpensive, self-administered test, SCENTinel 1.1 can discriminate between those with self-
- 505 reported normosmia and quantitative (i.e., anosmia or hyposmia), and qualitative (i.e., parosmia
- 506 and/or phantosmia) olfactory disorders with a high degree of accuracy. By assessing hedonics,
- 507 SCENTinel is a direct smell test that can rapidly capture self-reported parosmia. SCENTinel may
- 508 serve as a useful tool in research settings to assess smell function.
- 509

510 **Competing interests**

511 On behalf of the authors of this manuscript, the Monell Chemical Senses Center and Temple

512 University have been awarded patent protection (US patent no 11,337,640) and this patent has

513 been licensed to Ahersla Health, Inc. The authors may benefit financially through their

514 institution's patent policy.

515

516 **Author contributions**

517 SRH: manuscript writing and reviewing; MEH: conceptualization, pre-registration, data

518 collection, data analysis, manuscript writing and reviewing; RP: data analysis, manuscript

519 writing and reviewing; MAO: conceptualization, revision; NER: revision; DRR:

520 conceptualization, revision; PHD: conceptualization, revision; VP: conceptualization, pre-

521 registration, revision.

523 **Funding**

539 publication [48].

540

542 **References**

543 1. Rawal S, Hoffman HJ, Bainbridge KE, Huedo-Medina TB, Duffy VB. Prevalence and 544 risk factors of self-reported smell and taste alterations: results from the 2011-2012 US national 545 health and nutrition examination survey (NHANES). Chem Senses. 2016 Jan;41(1):69–76. 546 2. Bonfils P, Avan P, Faulcon P, Malinvaud D. Distorted odorant perception: analysis of a 547 series of 56 patients with parosmia. Arch Otolaryngol Head Neck Surg. 2005 Feb;131(2):107– 548 12. 549 3. Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, et al. 550 Position paper on olfactory dysfunction. Rhinology. 2016 Jan 31;56(1):1–30. 551 4. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life--an updated review. 552 Chem Senses. 2014 Mar;39(3):185–94. 553 5. Gerkin RC, Ohla K, Veldhuizen MG, Joseph PV, Kelly CE, Bakke AJ, et al. Recent 554 smell loss is the best predictor of COVID-19 among individuals with recent respiratory 555 symptoms. Chem Senses [Internet]. 2020 Dec 25 [cited 2021 Feb 11];(bjaa081). Available from: 556 https://doi.org/10.1093/chemse/bjaa081 557 6. CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. [cited 558 2022 June 28]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home 559 7. Hannum ME, Ramirez VA, Lipson SJ, Herriman RD, Toskala AK, Lin C, et al. Objective 560 sensory testing methods reveal a higher prevalence of olfactory loss in COVID-19–positive 561 patients compared to subjective methods: a systematic review and meta-analysis. Chem Senses. 562 2020 Nov 1;45(9):865–74. 563 8. Chiesa-Estomba CM, Lechien JR, Radulesco T, Michel J, Sowerby LJ, Hopkins C, et al. 564 Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. Eur J Neurol. 565 2020/08/05 ed. 2020 Nov;27(11):2318–21. 566 9. Sakalli E, Temirbekov D, Bayri E, Alis EE, Erdurak SC, Bayraktaroglu M. Ear nose 567 throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients. Am J 568 Otolaryngol. 2020/06/23 ed. 2020;41(6):102622–102622. 569 10. Vaira LA, Hopkins C, Petrocelli M, Lechien JR, Chiesa-Estomba CM, Salzano G, et al. 570 Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and 571 prospective study. J Laryngol Otol. 2020 Aug;134(8):703–9. 572 11. Reiter ER, Coelho DH, Kons ZA, Costanzo RM. Subjective smell and taste changes 573 during the COVID-19 pandemic: Short term recovery. Am J Otolaryngol. 2020 574 Dec; 41(6): 102639. 575 12. Moein ST, Hashemian SM, Tabarsi P, Doty RL. Prevalence and reversibility of smell 576 dysfunction measured psychophysically in a cohort of COVID-19 patients. Int Forum Allergy 577 Rhinol. 2020 Oct;10(10):1127-35. 578 13. Vihta K-D, Pouwels KB, Peto TE, Pritchard E, House T, Studley R, et al. Omicron-579 associated changes in SARS-COV-2 symptoms in the United Kingdom. Medrxiv. 2022 Jan 580 1;2022.01.18.22269082. 581 14. Ben Killingley, Alex Mann, Mariya Kalinova, Alison Boyers, Niluka Goonawardane, Jie 582 Zhou, et al. Safety, tolerability, and viral kinetics during SARS-cov-2 human challenge. Nat 583 Portf [Internet]. 2022 Feb 28; Available from: https://doi.org/10.21203/rs.3.rs-1121993/v1 584 15. Oleszkiewicz A, Kunkel F, Larsson M, Hummel T. Consequences of undetected 585 olfactory loss for human chemosensory communication and well-being. Philos Trans R Soc 586 Lond B Biol Sci. 2020 Jun 8;375(1800):20190265.

587 16. Rawal S, Hoffman HJ, Honda M, Huedo-Medina TB, Duffy VB. The Taste and Smell

588 Protocol in the 2011–2014 US National Health and Nutrition Examination Survey (NHANES): 589 test–retest reliability and validity testing. Chemosens Percept. 2015 Sep;8(3):138–48.

590 17. Dalton P, Hummel T. Chemosensory function and response in idiopathic environmental 591 intolerance. Occup Med Phila Pa. 2000 Sep;15(3):539–56.

592 18. Lötsch J, Hummel T. A machine-learned analysis suggests non-redundant diagnostic

593 information in olfactory subtests. IBRO Rep. 2019 Jun;6:64–73.

594 19. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell

595 Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 596 1984 Mar;32(3):489–502.

- 597 20. Doty RL, Marcus A, Lee WW. Development of the 12-Item Cross-Cultural Smell 598 Identification Test(CC-SIT). The Laryngoscope. 1996;106(3):353–6.
- 599 21. Kondo H, Matsuda T, Hashiba M, Baba S. A study of the relationship between the T&T

600 olfactometer and the University of Pennsylvania Smell Identification Test in a Japanese 601 population. Am J Rhinol. 1998 Oct;12(5):353–8.

602 22. Duff K, mccaffrey RJ, Solomon GS. The Pocket Smell Test. J Neuropsychiatry Clin 603 Neurosci. 2002 May 1;14(2):197–201.

- 604 23. Choudhury ES, Moberg P, Doty RL. Influences of age and sex on a microencapsulated 605 odor memory test. Chem Senses. 2003 Nov 1;28(9):799–805.
- 606 24. Jackman AH, Doty RL. Utility of a three-item smell identification test in detecting 607 olfactory dysfunction. The Laryngoscope. 2005 Dec;115(12):2209–12.
- 608 25. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' Sticks': Olfactory 609 performance assessed by the combined testing of odor identification, odor discrimination and
- 610 olfactory threshold. Chem Senses. 1997 Feb 1;22(1):39–52.
- 611 26. Croy I, Zehner C, Larsson M, Zucco GM, Hummel T. Test–retest reliability and validity
- 612 of the Sniffin' TOM Odor Memory Test. Chem Senses. 2015 Mar 1;40(3):173–9.
- 613 27. Liu DT, Welge-Lüssen A, Besser G, Mueller CA, Renner B. Assessment of odor hedonic 614 perception: the Sniffin' sticks parosmia test (ssparot). Sci Rep. 2020 Oct 22;10(1):18019.
- 615 28. Dalton P, Doty RL, Murphy C, Frank R, Hoffman HJ, Maute C, et al. Olfactory
- 616 assessment using the NIH Toolbox. Neurology. 2013 Mar 12;80(Issue 11, Supplement 3):S32–6.
- 617 29. Parma V, Hannum ME, O'Leary M, Pellegrino R, Rawson NE, Reed DR, et al.
- 618 SCENTinel 1.0: development of a rapid test to screen for smell loss. Chem Senses. 2021 Mar 27;
- 619 30. Landis BN, Frasnelli J, Croy I, Hummel T. Evaluating the clinical usefulness of
- 620 structured questions in parosmia assessment. The Laryngoscope. 2010 Aug;120(8):1707–13.
- 621 31. Pellegrino R, Mainland JD, Kelly CE, Parker JK, Hummel T. Prevalence and correlates
- 622 of parosmia and phantosmia among smell disorders. Chem Senses. 2021 Jan 1;46:bjab046.

623 32. Nordin S, Brämerson A, Millqvist E, Bende M. Prevalence of parosmia: the Skövde 624 population-based studies. Rhinology. 2007 Mar;45(1):50–3.

- 625 33. Leopold D. Distortion of olfactory perception: diagnosis and treatment. Chem Senses. 626 2002 Sep;27(7):611–5.
- 627 34. Frasnelli J, Landis BN, Heilmann S, Hauswald B, Hüttenbrink KB, Lacroix JS, et al.
- 628 Clinical presentation of qualitative olfactory dysfunction. Eur Arch Oto-Rhino-Laryngol Off J

629 Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 630 2004 Aug;261(7):411–5.

- 631 35. Keller A, Malaspina D. Hidden consequences of olfactory dysfunction: a patient report
- 632 series. BMC Ear Nose Throat Disord. 2013 Jul 23;13:8.

633 36. Ohla K, Veldhuizen MG, Green T, Hannum ME, Bakke AJ, Moein ST, et al. Increasing 634 incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss. 635 Medrxiv. 2021 Jan 1;2021.08.28.21262763. 636 37. Tognetti A, Thunell E, Olsson MJ, Greilert N, Havervall S, Thålin C, et al. High 637 prevalence of olfactory disorders 18 months after contracting COVID-19. Medrxiv. 2022 Jan 638 1;2022.01.20.22269490. 639 38. Said M, Luong T, Jang SS, Davis ME, deconde AS, Yan CH. Clinical factors associated 640 with lower health scores in COVID-19–related persistent olfactory dysfunction. Int Forum 641 Allergy Rhinol [Internet]. 2022 Jan 15 [cited 2022 Feb 4];n/a(n/a). Available from: 642 https://doi.org/10.1002/alr.22978 643 39. Deems DA, Doty RL, Settle RG, Moore-Gillon V, Shaman P, Mester AF, et al. Smell and 644 taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste 645 Center. Arch Otolaryngol Neck Surg. 1991 May 1;117(5):519–28. 646 40. Parker JK, Kelly CE, Smith B, Hopkins C, Gane SB. An analysis of patients' 647 perspectives on qualitative olfactory dysfunction using social media. JMIR Form Res. 2021; 648 41. Callahan CD, Hinkebein JH. Assessment of anosmia after traumatic brain injury: 649 performance characteristics of the University of Pennsylvania Smell Identification Test. J Head 650 Trauma Rehabil. 2002 Jun;17(3):251–6. 651 42. Callahan CD, Hinkebein J. Neuropsychological significance of anosmia following 652 traumatic brain injury. J Head Trauma Rehabil. 1999 Dec;14(6):581–7. 653 43. Bratt M, Skandsen T, Hummel T, Moen KG, Vik A, Nordgård S, et al. Frequency and 654 prognostic factors of olfactory dysfunction after traumatic brain injury. Brain Inj. 655 2018;32(8):1021–7. 656 44. Albers MW, Tabert MH, Devanand DP. Olfactory dysfunction as a predictor of 657 neurodegenerative disease. Curr Neurol Neurosci Rep. 2006 Sep;6(5):379–86. 658 45. Barresi M, Ciurleo R, Giacoppo S, Foti Cuzzola V, Celi D, Bramanti P, et al. Evaluation 659 of olfactory dysfunction in neurodegenerative diseases. J Neurol Sci. 2012 Dec 15;323(1–2):16– 24. 660 661 46. Dintica CS, Marseglia A, Rizzuto D, Wang R, Seubert J, Arfanakis K, et al. Impaired 662 olfaction is associated with cognitive decline and neurodegeneration in the brain. Neurology. 663 2019 Feb 12;92(7):e700–9. 664 47. Lee DY, Lee WH, Wee JH, Kim J-W. Prognosis of postviral olfactory loss: follow-up 665 study for longer than one year. Am J Rhinol Allergy. 2014 Sep 1;28(5):419–22. 666 48. Hannum M, Parma V, Pellegrino R, Dalton P, Reed D. Distinguishing qualitative smell 667 disorders from quantitative using the SCENTinel test. 2021 Jan 21 [cited 2021 Mar 18]; 668 Available from: https://osf.io/twu4e 669 49. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The redcap 670 consortium: building an international community of software platform partners. J Biomed 671 Inform. 2019 Jul 1;95:103208. 672 50. Ruopp, M. D., Perkins, N. J., Whitcomb, B. W. & Schisterman, E. F. Youden Index and 673 optimal cut-point estimated from observations affected by a lower limit of detection. *Biom. J.* 674 *Biom. Z.* **50**, 419–430 (2008). 675 51. Hsieh, J. W., Keller, A., Wong, M., Jiang, R.-S. & Vosshall, L. B. SMELL-S and 676 SMELL-R: Olfactory tests not influenced by odor-specific insensitivity or prior olfactory 677 experience. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 11275–11284 (2017).

- 678 52. Schönbrodt FD, Zehetleitner M, Wagenmakers E-J, Perugini M. Sequential hypothesis
- 679 testing with Bayes factors: efficiently testing mean differences. Psychol Methods.
- 680 2017;22(2):322–39.
- 681 53. R Core T. R: A language and environment for statistical computing. 2021;
- 682 54. Whitcroft KL, Cuevas M, Haehner A, Hummel T. Patterns of olfactory impairment
- 683 reflect underlying disease etiology. The Laryngoscope. 2017 Feb;127(2):291–5.
- 684 55. Parker JK, Kelly CE, Gane SB. Molecular mechanism of parosmia [Internet].
- 685 Otolaryngology; 2021 Feb [cited 2021 May 13]. Available from:
- 686 http://medrxiv.org/lookup/doi/10.1101/2021.02.05.21251085
- 687 56. Landis BN, Frasnelli J, Hummel T. Euosmia: A rare form of parosmia. Acta Otolaryngol 688 (Stockh). 2006 Jan 1;126(1):101–3.
- 689 57. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time
- 690 tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020 Jul 691 1;26(7):1037–40.
- 692 58. Kattar N, Do TM, Unis GD, Migneron MR, Thomas AJ, mccoul ED. Olfactory training
- 693 for postviral olfactory dysfunction: systematic review and meta-analysis. Otolaryngol--Head
- 694 Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2021 Feb;164(2):244–54.
- 695 59. Aldundag A, Yilmaz E, Kesimli MC. Modified olfactory training is an effective
- 696 treatment method for COVID-19 induced parosmia. The Laryngoscope [Internet]. 2022 Mar 7
- 697 [cited 2022 Mar 15];n/a(n/a). Available from: https://doi.org/10.1002/lary.30101
- 698 60. Lechien JR, Cabaraux P, Chiesa-Estomba CM, Khalife M, Hans S, Calvo-Henriquez C,
- 699 et al. Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-
- 700 19 patients. Head Neck. 2020 Jul;42(7):1583–90.

701 **Figure Captions**

736 Figure 1. Validation of the original SCENTinel 1.0 classification model. SCENTinel 1.1-738 discriminated anosmia and normosmia in a COVID-19-related population (teal color; n = 51 with 739 anosmia, 66 with normosmia) were well fitted to the original SCENTinel 1.0 classification 740 model. Melon color refers to the model performance of SCENTinel 1.0 with the original sample 741 (n = 111 with anosmia, 154 with normosmia). False positive and true positive rates corresponds 742 to the performance of the classification model to accurately predict an individual as someone 743 with 'anosmia' or someone with 'normosmia' based on their SCENTinel results.

745 Figure 2. Receiver operating characteristic (ROC) curves and statistics on SCENTinel 1.1 scores 747 overall and for single subtests across groups based on the linear discriminant analysis algorithm: 748 (A) individuals with normosmia (n = 66) versus quantitative dysfunction (n = 135); (B) 749 individuals with quantitative dysfunction versus qualitative dysfunction ($n = 86$); (C) individuals 750 with normosmia versus qualitative dysfunction. Quantitative dysfunction encompasses 751 individuals with anosmia or hyposmia; qualitative dysfunction includes individuals with 752 parosmia and/or phantosmia. Intensity and hedonics are continuous. AUC, area under the curve; 753 p, p-value; D, DeLong's test for 2 ROC curves; df, degrees of freedom. 754 755 756

758

Figure 3. Investigation of the hedonic score across individuals with or without parosmia. A) 760 Comparison of average hedonic score across individual smell groups ($N = 84$ with hyposmia, 66 761 with normosmia, 66 with parosmia). B) Relationship between hedonic score and frequency of

762 parosmia events (determined via participant's response to "How often have you experienced

763 smells being distorted or don't smell like they used to?"; $N = 66$). C) Comparison of average

764 hedonic score per odor across those with and without parosmia $(N = 150$ without parosmia, 66

765 with parosmia). D) Comparison of average hedonic rating and vomit rating across those with and

- 766 without parosmia. Error bars indicate standard deviation.
- 767

768
769

Figure 4. Summary of participants in the current study. Final smell group classifications

770 (quantitative, qualitative, mixed, and normosmia) were based on the self-report answers to the

771 question stated. Quantitative smell disorders are classified as those with a change in the

772 perceived intensity of odors. Qualitative smell disorders include those where the perceptual

773 quality or identity of an odor has changed. Thick-lined and dashed boxes are used in the final

774 analyses.

777 Note: # = response pattern number. Odor detection is by a triangle test. "First attempt" is a four-

alternative forced-choice. "Second attempt" is a three-alternative forced choice. 779

t

